Results 51 to 60 of about 3,560,828 (302)

Cluster Randomized Control Trial Flow Diagram.

open access: yes, 2016
Cluster Randomized Control Trial Flow Diagram.
Davoud Shojaeizadeh (2742352)   +8 more
core   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

Informed Consent and Cluster-Randomized Trials

open access: yesAmerican Journal of Public Health, 2012
We argue that cluster-randomized trials are an important methodology, essential to the evaluation of many public health interventions. However, in the case of at least some cluster-randomized trials, it is not possible, or is incompatible with the aims of the study, to obtain individual informed consent.
Julius, Sim, Angus, Dawson
openaire   +3 more sources

Consort flow diagram for cluster randomized trial.

open access: yes, 2013
Consort flow diagram for cluster randomized trial.
Baido Nassirou (106584)   +12 more
core   +1 more source

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

open access: yesMolecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic   +10 more
wiley   +1 more source

Selection bias and subject refusal in a cluster-randomized controlled trial

open access: yesBMC Medical Research Methodology, 2017
Background Selection bias and non-participation bias are major methodological concerns which impact external validity. Cluster-randomized controlled trials are especially prone to selection bias as it is impractical to blind clusters to their allocation ...
Rochelle Yang   +5 more
doaj   +1 more source

Cluster identification, selection, and description in cluster randomized crossover trials: the PREP-IT trials

open access: yesTrials, 2020
Background In cluster randomized crossover (CRXO) trials, groups of participants (i.e., clusters) are randomly allocated to receive a sequence of interventions over time (i.e., cluster periods).
Sheila Sprague   +17 more
doaj   +1 more source

Improved Designs for Cluster Randomized Trials [PDF]

open access: yesAnnual Review of Public Health, 2016
Studies in which clusters of individuals are randomized to conditions are increasingly common in public health research. However, the designs utilized for such studies are often suboptimal and inefficient. We review strategies to improve the design of cluster randomized trials. We discuss both older but effective design concepts that are underutilized,
openaire   +2 more sources

Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial. [PDF]

open access: yes, 2012
BACKGROUND: Trachoma control programs utilize mass azithromycin distributions to treat ocular Chlamydia trachomatis as part of an effort to eliminate this disease world-wide. But it remains unclear what the community-level risk factors are for infection.
Jeremy D Keenan   +56 more
core   +2 more sources

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy